insurance changes glp 1 MCT2D Navigating Changes to GLP-1 Medication
Description
Then, your medical team schedules regular follow-ups to review progress and fine-tune your plan
Lilly and Novo Nordisk also presented findings at the diabetes conference
73 Fewer studies have evaluated the risk of biliary disease, possibly due to impaired gallbladder emptying, 74 however, tirzepatide was shown to portend an increased risk (RR 1.97, 95% CI 1.143.42, I2 = 0.0%, p = 0.558)
However, the rising volume of complaints has prompted regulatory scrutiny and may open the door to further litigation
